Abstract
The ECHELON-1 trial (NCT01712490) demonstrated superior progression-free survival for brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with frontline stage III/IV Hodgkin lymphoma with a median follow-up of 2 years and superior overall survival (OS) with a median follow-up of 6 years. The objective of this study was to compare the long-term survival extrapolations using trial data from early vs late datacuts.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
